Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 15/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | GIPR | P48546 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9894696 | 0.89 | TRPV1 (0.41) | GCGRTRPV1DHODHGIPRCYP3A4 | |
| SCHEMBL9896545 | 0.89 | TRPV1 (0.41) | GCGRTRPV1DHODHGIPRCYP3A4 | |
| SCHEMBL205772 | 0.85 | TRPV1 (0.42) | GCGRTRPV1EPHX2NR1H4DHODH | |
| SCHEMBL9897780 | 0.83 | TRPV1 (0.40) | GCGRTRPV1EPHX2NR1H4DHODH | |
| SCHEMBL204709 | 0.82 | TRPV1 (0.46) | GCGRTRPV1EPHX2NR1H4DHODH | |
| SCHEMBL9897782 | 0.82 | TRPV1 (0.41) | GCGRTRPV1EPHX2NR1H4DHODH | |
| SCHEMBL203091 | 0.81 | TRPV1 (0.42) | GCGRTRPV1DHODH | |
| SCHEMBL205272 | 0.80 | TRPV1 (0.44) | GCGRTRPV1DHODHGIPRCYP3A4 | |
| SCHEMBL204527 | 0.80 | TRPV1 (0.44) | GCGRTRPV1DHODHGIPRCYP3A4 | |
| SCHEMBL202741 | 0.79 | TRPV1 (0.45) | GCGRTRPV1DHODHGIPRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149750-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149750-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | CYP4X1, CBR3, TYR | GCGR 1177/4885TRPV1 4024/4885EPHX2 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.